1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Biosceptre International Limited - Product Pipeline Review - 2014

Biosceptre International Limited - Product Pipeline Review - 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 21 pages

Biosceptre International Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Biosceptre International Limited - Product Pipeline Review - 2014’, provides an overview of the Biosceptre International Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biosceptre International Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Biosceptre International Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Biosceptre International Limited’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Biosceptre International Limited’s pipeline products

Reasons to buy

- Evaluate Biosceptre International Limited’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Biosceptre International Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Biosceptre International Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Biosceptre International Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biosceptre International Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Biosceptre International Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Biosceptre International Limited - Product Pipeline Review - 2014
Table of Contents

Biosceptre International Limited Snapshot 4
Biosceptre International Limited Overview 4
Key Information 4
Key Facts 4
Biosceptre International Limited - Research and Development Overview 5
Key Therapeutic Areas 5
Biosceptre International Limited - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Biosceptre International Limited - Pipeline Products Glance 9
Biosceptre International Limited - Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Biosceptre International Limited - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Biosceptre International Limited - Drug Profiles 11
BIL-010t 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Cell Therapy for Gastrointestinal Tumor 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
BIL-221s 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Biosceptre International Limited - Pipeline Analysis 14
Biosceptre International Limited - Pipeline Products by Target 14
Biosceptre International Limited - Pipeline Products by Route of Administration 15
Biosceptre International Limited - Pipeline Products by Molecule Type 16
Biosceptre International Limited - Pipeline Products by Mechanism of Action 17
Biosceptre International Limited - Recent Pipeline Updates 18
Biosceptre International Limited - Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 21
Disclaimer 21

List of Tables

Biosceptre International Limited, Key Information 4
Biosceptre International Limited, Key Facts 4
Biosceptre International Limited - Pipeline by Indication, 2014 6
Biosceptre International Limited - Pipeline by Stage of Development, 2014 7
Biosceptre International Limited - Monotherapy Products in Pipeline, 2014 8
Biosceptre International Limited - Phase I, 2014 9
Biosceptre International Limited - Preclinical, 2014 10
Biosceptre International Limited - Pipeline by Target, 2014 14
Biosceptre International Limited - Pipeline by Route of Administration, 2014 15
Biosceptre International Limited - Pipeline by Molecule Type, 2014 16
Biosceptre International Limited - Pipeline Products by Mechanism of Action, 2014 17
Biosceptre International Limited - Recent Pipeline Updates, 2014 18

List of Figures

Biosceptre International Limited - Pipeline by Top 10 Indication, 2014 6
Biosceptre International Limited - Pipeline by Stage of Development, 2014 7
Biosceptre International Limited - Monotherapy Products in Pipeline, 2014 8
Biosceptre International Limited - Pipeline by Top 10 Target, 2014 14
Biosceptre International Limited - Pipeline by Top 10 Route of Administration, 2014 15
Biosceptre International Limited - Pipeline by Top 10 Molecule Type, 2014 16
Biosceptre International Limited - Pipeline Products by Top 10 Mechanism of Action, 2014 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.